The doctor said that 132 patients in the United States and Australia who took the drug vemurafenib gained a few extra months of life. 【Ming Youjing Chun Optimization Room QQ contact 466401604883847810 product keywords guaranteed 4 on Baidu's front page, website included for eight thousand per year! Contact number 13422475786】 Prior to this, there had been no new drugs for cancer for over a decade, www.bohuicn.com. Using tanning beds and sunlamps may also increase the risk of developing melanoma " Facing these uncertainties, and with the current drug targeting British cancer patients, it will be interesting to see the price the manufacturer charges, as there is already significant pressure on scarce healthcare resources." According to the European Medicines Agency, the drug has been recommended for approval in Europe, pending final approval by the European Commission. Melanoma is responsible for most deaths from skin cancer. The treatment is a drug for advanced melanoma that was approved quickly last year in the U.S., providing hope for patients with advanced melanoma.
Starting report Kate Law Research published in the British Medical Journal found that those in the study survived an average of 16 months, compared to nine months with conventional treatment. Melanoma is relatively rare, accounting for 10% of all skin cancer cases. Melanoma, also known as malignant melanoma, is a type of skin cancer that is aggressive and dangerous. Approximately 2000 people die annually in the UK and Wales due to melanoma. Malignant melanoma " Cancer Research UK Drug Resistance " About half of these treatments seem to benefit, so it has the potential to help about a quarter of all advanced melanoma patients overall. But she said there are still questions that remain unanswered, not just regarding cost. In the UK, patients will be eligible for the Cancer Drugs Fund, the charity said. Elizabeth Woolf, head of Cancer Information Website Help UK at Cancer Research UK, said: "This is an interesting, impressive, but relatively small trial of a promising new generation of melanoma drugs, which Cancer Research UK is proud to have played a role in developing." Kate Law, Head of Clinical and Population Research at Cancer Research UK, stated that the treatment represents a new generation of anti-cancer drugs targeted at specific patient genetic makeup. Cancer Research UK said that once the drug is approved in Europe, patients will be able to discuss treatment options with their doctors.
"We need to do a series of studies to resolve the issue of resistance with these targeted drugs," she continued reading the main story. She told the BBC: "This is not a cure - you're talking about an extra six months of life. "These results tell us that this drug has a very significant impact, changing how we treat metastatic melanoma." (Yieyang Network Company www.wji.cc) Dr. Anthony Ribas, professor of Hematology/Oncology and researcher at the Anderson Cancer Center at UCLA, said: "This study shows that Zelboraf changes the natural history of the disease. This data exceeded my expectations. Vemurafenib targets approximately half of the patients with advanced melanoma whose tumors express a specific gene mutation.
Continuing to read the main story "Everyone in the drug trial, so we can't tell how great the benefit is compared to those without it or with other treatments. Due to the drug's target, only half of all melanoma patients qualify. Vemurafenib (Zelboraf) has been recommended for approval in Europe. "We saw a large number of patients with lasting responses to the drug, and the entire group of patients no longer live. Although it provides hope, she said, it is not a cure as the cancer eventually becomes resistant to the drug. A new treatment for advanced skin cancer almost doubles survival time according to an international study.
"The main cause of melanoma is considered to be excessive exposure to the sun." Related subject articles: Is McIlroy Contact Number 13422475786] All job seekers 5-megapixel camera If detected early